Isodiol International Inc. Introduces Isoderm Direct Effects Technology Nationally Via PBS Television
July 31, 2018 – Vancouver, BC – Isodiol International Inc. (CSE: ISOL) (OTC:ISOLD) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global CBD innovator specializing in hemp-based health and wellness products, the development of pharmaceutical CBD delivery methods, and the manufacturing of pure, natural CBD as an Active Pharmaceutical Ingredient (API) for use in Finished Pharmaceutical Products (FPPs), is proud to announce it has been included as a show segment on the national PBSseries “American Health Journal – Innovations in Medicine.” The featured segment highlights CBD, its benefits in treating neurological conditions and associated pain, as well as a patented drug delivery system.
“At American Health Journal, on PBS, we’re always on the search for medical innovation, transformation and disruption as told by top doctors,” says AHJ Global Executive Producer, Michael Lesner. “Dr. Ronald Aung-Din, a prominent neurosurgeon from Sarasota, Florida, has provided us with a preview of this new product line based on Direct Effects Technology. He has given us a first important look into the future of CBD.”
“We are proud to be included in this PBS program, the longest continuously-airing medical show of its kind. We believe it is an important step in establishing medical credibility for our Company and Isoderm,” says Isodiol International CEO, Marcos Agramont.
To view the segment featuring Dr. Ronald Aung-Din and Isoderm, visit our website: isodiol.com/direct-effects-technology.
About “The American Health Journal”
“The American Health Journal” is a public television series that has been dedicated to informing the public on prevention, treatments, research, and the latest advancements in medicine. The series has won over 100 National and International awards since 1988. AHJ reaches over 118 million PBS viewers and 46 million households.
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products and most recently received approval as having the first CBD designated as an Active Pharmaceutical Ingredient as was announced April 26, 2018.
Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
ON BEHALF OF THE BOARD
“Marcos Agramont” CEO & Director
COMPANY MEDIA :
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.